Searching for Janoshik tirzepatide? Here is what that actually means in the UK

You have found Janoshik mentioned alongside tirzepatide, here is the context

Picture this: you have been reading weight-loss forums, someone mentions dramatic results with tirzepatide, and a commenter says they sourced it through Janoshik. It sounds like an insider tip. The reality is more complicated. Janoshik Laboratories is a third-party analytical chemistry service based in the Czech Republic. It performs purity and identity testing on chemical substances, publishing certificates of analysis that some grey-market vendors use as a credibility signal. The lab itself does not sell medicines; it tests whatever customers send it.

The substances being tested in this context are typically research chemicals or peptides, sold without the regulatory framework that applies to licensed human medicines. That matters for one straightforward reason: a certificate of analysis from an independent lab tells you what a sample contained on the day it was tested. It does not tell you about manufacturing consistency, sterility, storage conditions during transit, accurate dosing across batches, or any of the other safeguards that MHRA licensing requires Eli Lilly to demonstrate repeatedly and transparently. A common misconception is that a third-party purity test makes an unlicensed substance equivalent to a licensed medicine. It does not, the certificate covers chemistry, not the full safety picture.

The NHS medicines page for tirzepatide is a useful reference for understanding what the licensed medicine involves. And if you want a fuller picture of the treatment itself, the tirzepatide overview on this site explains the mechanism, the licensed strengths, and what clinical supervision looks like in practice.

What the MHRA says about unlicensed tirzepatide and counterfeit weight-loss pens

The regulatory picture has sharpened considerably over the past two years. In October 2025 the MHRA raided the first illicit UK manufacturing site producing counterfeit tirzepatide pens, in Northampton. Across 2025 enforcement activity recovered approximately 20 million doses of illegally traded weight-loss medicines with an estimated street value of around £45 million. These are not edge cases involving a handful of unlucky buyers; this is a large, active supply chain operating outside any safety framework.

Fake pens carry risks that a purity certificate cannot capture. Earlier MHRA warnings flagged counterfeit weight-loss products that contained insulin, a substance that can cause life-threatening hypoglycaemia in someone who does not have diabetes and has not been assessed for it. The dose in an unlicensed pen may be accurate, zero, or wildly higher than labelled. Sterility cannot be assumed. If something goes wrong, there is no adverse-event reporting trail, no Yellow Card follow-up, and no prescriber who knows you are taking it.

You can report a suspect seller or a suspected adverse reaction directly through the MHRA's Yellow Card scheme. Doing so helps protect other people. If you are weighing up private treatment options more broadly, the Mounjaro price comparison page sets out what legitimate private costs look like and what a transparent price actually covers.

The licensed route: what clinical supervision changes about tirzepatide treatment

Licensed Mounjaro (tirzepatide in its approved UK form) starts at 2.5 mg, a dose chosen specifically to let your system adjust before any therapeutic increase. The prescriber titrates from there based on your response, your tolerance, and your clinical picture, and if you are curious how that progression works at a specific point in the programme, our page on tirzepatide 10 explains what that stage of treatment involves. That titration process is not bureaucracy; it is the mechanism by which serious side effects are caught early and doses are matched to individuals rather than applied uniformly.

NICE recommended tirzepatide for NHS use in December 2024 under Technology Appraisal TA1026, reflecting the strength of the clinical evidence behind the licensed programme. Private treatment through a regulated pharmacy is available to people who meet the licensed eligibility criteria but are not yet in scope for NHS access or would prefer not to wait. At nume (sorry, at our pharmacy) every consultation is personally read by a GPhC-registered Independent Prescriber, not software. If approved, treatment is dispatched the same day for free next-working-day DPD delivery.

You can verify any online pharmacy on the GPhC register at pharmacyregulation.org/registers before handing over any personal or health information. For a broader look at how weight-loss treatment works, the weight-loss treatments overview covers what to expect from a clinically supervised programme. If you want to understand how Mounjaro and tirzepatide relate to each other, this page on Mounjaro versus tirzepatide explains the naming clearly. And if you have specific questions for a prescriber, our support team is available seven days a week.

The consultation itself is free. Speak to our prescribers to find out whether you are clinically suitable for licensed tirzepatide treatment through the nume consultation page, and if you would like to read ahead about higher maintenance doses, our pages on tirzepatide 30 and tirzepatide l cover what those stages of the programme look like.